Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.

scientific article published on 13 October 2015

Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/MP.2015.158
P932PMC publication ID4960445
P698PubMed publication ID26460229
P5875ResearchGate publication ID282874580

P50authorDavid J. BondQ52146724
Mauricio KunzQ56935942
Beny LaferQ42305969
Roumen MilevQ42317690
Raymond W. LamQ42883552
P2093author name stringF Kapczinski
J Quevedo
V Sharma
H Qian
H Wong
L N Yatham
L T Young
A Schaffer
M Kauer-Sant'Anna
S V Parikh
S Beaulieu
R Dias
A da Cunha
P Baruch
P H Silverstone
N Walji
A Daigneault
P2860cites workManual for the Extrapyramidal Symptom Rating Scale (ESRS).Q50279993
Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.Q52900826
Obesity in Patients With Bipolar DisorderQ57452985
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patientsQ69903875
A rating scale for depressionQ24564540
Polarity index of pharmacological agents used for maintenance treatment of bipolar disorderQ28250466
A New Depression Scale Designed to be Sensitive to ChangeQ29614720
A rating scale for mania: reliability, validity and sensitivityQ29619299
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.Q34486939
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorderQ34649187
Obesity in patients with bipolar disorder: a biopsychosocial-behavioral modelQ36539425
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for PsychopharmacologyQ37426143
Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trialQ38376022
Antipsychotic agents and bipolar disorder.Q41692615
Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorderQ43130555
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.Q44142664
Obesity as a correlate of outcome in patients with bipolar I disorderQ44265285
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneQ44824135
Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).Q46086886
The long-term natural history of the weekly symptomatic status of bipolar I disorderQ46317822
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).Q46519540
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.Q47208132
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized studyQ48310435
A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorderQ48697520
P275copyright licenseCreative Commons Attribution-NonCommercial-NoDerivs 4.0 InternationalQ24082749
P6216copyright statuscopyrightedQ50423863
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectrisperidoneQ412443
manic episodeQ18966903
P304page(s)1050-1056
P577publication date2015-10-13
P1433published inMolecular PsychiatryQ6895973
P1476titleOptimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial
P478volume21

Reverse relations

cites work (P2860)
Q39116844Antipsychotic adjunctive therapy to mood stabilizers and 1-year rehospitalization rates in bipolar disorder: A cohort study
Q37197203Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods
Q52656684Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Q89665749Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better
Q53742036Defining the role of SGAs in the long-term treatment of bipolar disorder.
Q89665776Evidence-Based Principles for Bipolar Disorder Treatment
Q34676317Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
Q52661474Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder.
Q47863136Psychopharmacological treatment of psychotic mania and psychotic bipolar depression compared to non-psychotic mania and non-psychotic bipolar depression
Q47553353Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Q94569502Stabilization Beyond Mood: Stabilizing Patients With Bipolar Disorder in the Various Phases of Life
Q28066714The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Search more.